Literature DB >> 17932664

The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates.

Oliver Burk, Matthias Schwab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17932664     DOI： 10.1007/s00228-007-0393-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  16 in total

1.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

2.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

Authors:  V Ozdemir; W Kalow; B K Tang; A D Paterson; S E Walker; L Endrenyi; A D Kashuba
Journal:  Pharmacogenetics       Date:  2000-07

3.  Bimodal distribution of renal cytochrome P450 3A activity in humans.

Authors:  B D Haehner; J C Gorski; M Vandenbranden; S A Wrighton; S K Janardan; P B Watkins; S D Hall
Journal:  Mol Pharmacol       Date:  1996-07       Impact factor: 4.436

4.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

5.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

Authors:  J C Gorski; S D Hall; D R Jones; M VandenBranden; S A Wrighton
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

6.  Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.

Authors:  Weili Huang; Yvonne S Lin; Donavon J McConn; Justina C Calamia; Rheem A Totah; Nina Isoherranen; Mary Glodowski; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2004-09-21       Impact factor: 3.922

Review 7.  Genetic variability in CYP3A5 and its possible consequences.

Authors:  Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

8.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

Authors:  Anna Westlind-Johnsson; Sarah Malmebo; Anna Johansson; Charlotta Otter; Tommy B Andersson; Inger Johansson; Robert J Edwards; Alan R Boobis; Magnus Ingelman-Sundberg
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

9.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

10.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

Authors:  Yvonne S Lin; Amy L S Dowling; Sean D Quigley; Federico M Farin; Jiong Zhang; Jatinder Lamba; Erin G Schuetz; Kenneth E Thummel
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436
View more
  1 in total

1.  Effect of danshen extract on the activity of CYP3A4 in healthy volunteers.

Authors:  Furong Qiu; Guangji Wang; Rong Zhang; Jianguo Sun; Jian Jiang; Yueming Ma
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.